Page last updated: 2024-12-05
benzobarbital
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
benzobarbital: for drug therapy of epilepsy [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 12938 |
| CHEMBL ID | 1338506 |
| SCHEMBL ID | 2109448 |
| MeSH ID | M0043743 |
Synonyms (46)
| Synonym |
|---|
| 744-80-9 |
| AC-19990 |
| STL301913 |
| 5-ethyl-5-phenyl-1-(phenylcarbonyl)pyrimidine-2,4,6(1h,3h,5h)-trione |
| OPREA1_179037 |
| barbituric acid, 1-benzoyl-5-ethyl-5-phenyl- |
| benzonalum |
| benzobarbital |
| 2,4,6(1h,3h,5h)-pyrimidinetrione, 1-benzoyl-5-ethyl-5-phenyl- |
| benzoylluminal |
| benzobarbitalum [inn-latin] |
| 5-ethyl-1-benzoyl-5-phenylbarbituric acid |
| brn 0627140 |
| 1-benzoyl-5-ethyl-5-phenylbarbituric acid |
| benzobarbital [inn] |
| benzoyluminal |
| 1-benzoyl-5-ethyl-5-phenyl-2,4,6-trioxohexahydropyrimidine |
| benzonal |
| benzoylphenobarbital |
| NCGC00160414-01 |
| 1-benzoyl-5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione |
| A838147 |
| 5-ethyl-5-phenyl-1-(phenylcarbonyl)-1,3-diazinane-2,4,6-trione |
| benzobarbital:1-benzoyl-5-ethyl-5-phenyl barbitoric acid |
| dtxsid1046138 , |
| dtxcid9026138 |
| cas-744-80-9 |
| tox21_111797 |
| CHEMBL1338506 |
| unii-ynj78bd0ah |
| ynj78bd0ah , |
| 5-24-09-00293 (beilstein handbook reference) |
| benzobarbitalum |
| AKOS015896461 |
| benzobarbital [who-dd] |
| benzobarbital [mart.] |
| 1-benzoyl-5-ethyl-5-phenylpyrimidine-2,4,6(1h,3h,5h)-trione |
| J-504234 |
| SCHEMBL2109448 |
| QMOWPJIFTHVQMB-UHFFFAOYSA-N |
| sr-01000212063 |
| SR-01000212063-1 |
| 1-benzoyl-5-ethyl-5-phenyl-2,4,6(1h,3h,5h)-pyrimidinetrione |
| Q4083796 |
| AS-14647 |
| E79243 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "Administration of phenobarbital, benzonal and benzobamil in a dose of 1/20 of LD50 to rats was shown to be followed by phase changes in the system of microsomal oxidation of the liver--activation in the first days after administration with the subsequent (in 1-3 months) decrease of the activity." | ( [Effect of anticonvulsant agents, inducers of microsomal oxidation, on the B-link of immunity and on the natural cytotoxicity of lymphoid organ cells in rats]. Cherevko, NA; Galenko, OA; Novozheeva, TP; Potapova, GV; Saratikov, AS, ) | 0.13 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic parameters of this metabolite (PB) were determined in guinea-pigs, and their identity with the pharmacokinetic parameters of PB as the parent drug was confirmed." | ( Use of normal-phase microcolumn high-performance liquid chromatography for the study of hydrolytic stability, metabolic profiling and pharmacokinetics of an antiepileptic drug, benzonal. Chankvetadze, BG; Okujava, VM; Rogava, MM; Rukhadze, MD; Tkesheliadze, NB, 1991) | 0.28 |
| "Major pharmacokinetic parameters of the Soviet anticonvulsive drug benzobarbital used with different regimens of administration (single and prolonged) are described." | ( [Pharmacokinetic aspects of anticonvulsant therapy with benzonal]. Antadze, ZI; Chanvetadze, BG; Chkhenkeli, SI; Okudzhava, VM; Rukhadze, MD, 1988) | 0.51 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The most common of these causes include malpractice of the dosage build-up in the absence of the clinical effect, polytherapy--not infrequently with drugs of the same chemical group, and insufficient attention to the potentiating drug interaction." | ( [Phenomenon of "paradoxical poisoning" during antiepileptic therapy]. Geladze, TSh, 1986) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 28.1838 | 0.0123 | 7.9835 | 43.2770 | AID1346984 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 28.1838 | 0.0054 | 28.0263 | 1,258.9301 | AID1346985 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 33.4915 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 112.2020 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 9.0743 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (42)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 22 (52.38) | 18.7374 |
| 1990's | 13 (30.95) | 18.2507 |
| 2000's | 3 (7.14) | 29.6817 |
| 2010's | 3 (7.14) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 31.17
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.17) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (4.48%) | 5.53% |
| Reviews | 3 (4.48%) | 6.00% |
| Case Studies | 2 (2.99%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 59 (88.06%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||